News: Oncolytics Biotech Completes Initial Scale-Up of Manufacturing Process for Reolysin. Genetic Engineering News - Biotechnology from Bench to Busi

News: Oncolytics Biotech Completes Initial Scale-Up of Manufacturing Process for Reolysin. Genetic Engineering News - Biotechnology from Bench to Business: "Oncolytics Biotech reports the successful initial scale-up of the manufacturing process for its anticancer candidate. Reolysin is a formulation of the human reovirus and is in clinical trials for treating Ras-activated tumor cells and some cellular proliferative disorders."